Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Todd S. ThomsonDirector | Actuate TherapeuticsACTU | Open-market sale | 01/05 | 01/07 | 280,000 sh | $5.80 | $1,624,000 | −23.6% |
Kairos Venture Partners IIDirector | Actuate TherapeuticsACTU | Open-market sale | 01/05 | 01/07 | 280,000 sh | $5.80 | $1,624,000 | −23.6% |
Bios Fund IDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Fund I QPDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Fund IIDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Fund II QPDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Fund II NTDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Actuate Co-Invest IDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Aaron G.L. FletcherDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Fund III NTDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Fund III QPDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Fund IIIDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Cavu ManagementDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Cavu AdvisorsDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
BP DirectorsDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Equity Partners IIDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Equity PartnersDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Leslie W. KreisDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Advisors GPDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |
Bios Capital ManagementDirector | Actuate TherapeuticsACTU | Open-market buy | 25/06/27 | 25/06/30 | 71,428 sh | $7.00 | $499,996 | +57.1% |